Tag: Prolong Pharmaceuticals
Prolong Pharmaceuticals gains US FDA fast-track designation for novel stroke therapy
Prolong Pharmaceuticals has announced that its investigational therapy—PEGylated carboxyhemoglobin, bovine (PP-007)—has received a fast-track designation from the US Food and Drug Administration (FDA) for...
